Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 112.71% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 40.93M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 40.93M.
Overvalued
The company’s latest PE is -2.86, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 23.44M shares, decreasing 19.96% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 15.93K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.10.